Please assess the completion status of the following clinical trial:

Trial Title: Fecal Transplant for MDR Pathogen Decolonization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Renal transplant patient inclusion criteria:~* 18 years or older~* Able to provide informed consent~* Positive for one of the target MDR organisms by rectal or stool culture tests~FMT stool donor inclusion criteria:~* Able to provide informed consent~* Able to complete donor screening~* Able to adhere to FMT stool collection and testing procedures~Renal transplant patient exclusion criteria:~* Still in hospital at week 7 following organ transplantation~* Pregnant or planning to become pregnant~* Breastfeeding~* Participating in another interventional or investigational study~* Neutropenic (ANC \< 0.5)~* Colonized with Clostridium difficile~* Presence of colostomy or ileostomy~* Has an active intestinal infection~* Fever \> 38.0 or WBC count \> 15,000~* Are taking a non-dietary probiotic supplement~* Require or are expected to require systemic antimicrobial therapy other than Pneumocystis prophylaxis or cytomegalovirus (CMV) therapy during the study period~* Has a severe underlying disease with anticipated survival less than 6 months~* Are unable to tolerate FMT or enema for any reason, or where their physician believes for any reason that FMT might pose a health risk to the subject~* Subjects who report a history of anaphylactoid food allergy will not be excluded but these allergies will be noted and donors will be required to avoid ingestion of these foods for at least three days prior to donation~FMT stool donor exclusion criteria:~* Presence of any of the following by stool examination: vancomycin-resistant Enterococci (VRE), Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia, Campylobacter, ESBL or carbapenemase-producing Enterobacteriaceae (CRE), pathogenic ova or parasites, C. difficile toxin B (by PCR), or rotavirus, adenovirus and norovirus~* History of any type of active cancer aside from melanoma~* Risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any neurological disease as determined by the donor questionnaire~* History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation or diarrhea, or colostomy or ileostomy~* Receipt of blood transfusion from a country other than Canada in the preceding 6 months~* Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool donation~* Receipt of any live vaccine within 3 months prior to stool donation~* Any current or previous medical or psychosocial condition or behaviors which in the opinion of the investigator may pose risk to the recipients or the donor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).